Literature DB >> 7505343

Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation.

D H Gutmann1, G I Tennekoon, J L Cole, F S Collins, J L Rutkowski.   

Abstract

Neurofibromin, the product of the neurofibromatosis type 1 (NF1) gene, is a approximately 250 kDa protein expressed predominantly in cortical neurons and oligodendrocytes in the central nervous system (CNS) and sensory neurons and Schwann cells in the peripheral nervous system (PNS). To gain insight into the biological role of neurofibromin in Schwann cells, the modulation of NF1 gene expression in a Schwann cell line (MT4H1) stimulated to either proliferate or differentiate in response to agents that elevate intracellular cAMP was examined. Untreated cells and cells exposed to mitogenic doses of forskolin (1-10 microM) or 8-bromo-cAMP (0.1 mM) expressed low levels of NF1 mRNA and the protein was barely detectable. High doses of forskolin (100 microM) or 8-bromo-cAMP (1 mM) induced the expression of both myelin P0 protein and neurofibromin with an identical time course. Although NF1 mRNA levels peaked within 1-6 hr, the rise in neurofibromin was not apparent until 24-48 hr and peaked 72 hr after treatment. P0 and neurofibromin were also coinduced by cell-cell contact in high density, untreated cultures. Moreover, differentiation initiated by either cAMP stimulation or high density culture conditions was associated with predominant expression of the type 2 NF1 mRNA isoform. In contrast, type 1 NF1 mRNA isoform expression was observed in untreated Schwann cells or those stimulated with mitogenic doses of forskolin or 8-bromo-cAMP. A switch from the type 1 neurofibromin that can efficiently downregulate p21-ras to the type 2 isoform with reduced activity may facilitate a p21-ras signaling pathway associated with Schwann cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505343     DOI: 10.1002/jnr.490360212

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  7 in total

Review 1.  The NF1 gene in tumor syndromes and melanoma.

Authors:  Maija Kiuru; Klaus J Busam
Journal:  Lab Invest       Date:  2017-01-09       Impact factor: 5.662

2.  Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas.

Authors:  M Platten; M J Giordano; C M Dirven; D H Gutmann; D N Louis
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

3.  A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis.

Authors:  Carlos Riveros; Drew Mellor; Kaushal S Gandhi; Fiona C McKay; Mathew B Cox; Regina Berretta; S Yahya Vaezpour; Mario Inostroza-Ponta; Simon A Broadley; Robert N Heard; Stephen Vucic; Graeme J Stewart; David W Williams; Rodney J Scott; Jeanette Lechner-Scott; David R Booth; Pablo Moscato
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

Review 4.  Molecular genetics of neurofibromatosis type 1 (NF1).

Authors:  M H Shen; P S Harper; M Upadhyaya
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

5.  Lack of NF1 expression in a sporadic schwannoma from a patient without neurofibromatosis.

Authors:  D H Gutmann; I Silos-Santiago; R T Geist; M Daras; J L Rutkowski
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

6.  Differences in proliferation and invasion by normal, transformed and NF1 Schwann cell cultures are influenced by matrix metalloproteinase expression.

Authors:  D Muir
Journal:  Clin Exp Metastasis       Date:  1995-07       Impact factor: 5.150

7.  Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.

Authors:  Josep Biayna; Helena Mazuelas; Bernat Gel; Ernest Terribas; Gabrijela Dumbovic; Inma Rosas; Juana Fernández-Rodriguez; Ignacio Blanco; Elisabeth Castellanos; Meritxell Carrió; Conxi Lazaro; Eduard Serra
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.